Primrose Bio offers mRNA manufacturing solutions for RNA-based vaccines and therapeutics, including both ready-to-use and custom Prima RNApols™ designed to improve mRNA synthesis and in vitro transcription (IVT) consistency. Built on deep enzyme engineering and manufacturing expertise, Prima RNApols give mRNA developers greater control over yield and product quality with reduced input requirements. This delivers predictable IVT performance during process development at lower cost.
The Prima RNApols portfolio is designed to meet a range of program needs and DNA template requirements. Ready-to-use Prima RNApols are validated, consistent, and available in reagent and GMP-grades for rapid product development. For programs with more specific requirements, Primrose collaborates closely with partners to design custom RNA polymerases tailored to defined quality attributes, cost targets, and manufacturing objectives. This dual approach gives teams the right balance of speed, customization, and performance.
Prima RNApols are built for demanding mRNA applications, including long templates and self-amplifying RNA. Polymerase choice strongly impacts yield, dsRNA levels, and capping efficiency. By reducing dsRNA and other reaction byproducts while improving reagent efficiency, Prima RNApols can simplify downstream processing and improve overall process economics.
Together, the Prima RNApols portfolio reduces variability, aligns enzyme performance with target product profiles, and expands the range of mRNA constructs that can be manufactured reliably at scale.
WEBINARS AND VIDEOS
Polymerase Selection And Its Impact On IVT Outcomes For Self-Amplifying RNA
Polymerase selection has measurable consequences for IVT outcomes in saRNA production, affecting dsRNA byproduct levels, capping efficiency, total yield, and transcript integrity across long templates.
Strategies To Reduce mRNA Manufacturing Costs
Raw materials like cap analog, DNA template, and RNA polymerase can account for the majority of mRNA manufacturing costs. Examine data on reducing concentrations of each without compromising yield or capping efficiency.
Double Stranded RNA Formation And How RNA Polymerase Choice Can Reduce It
T7 polymerase generates substantial dsRNA in IVT reactions. Non-T7 alternatives tell a different story, and the data makes a compelling case for reconsidering your enzyme selection.
Engineered RNA Polymerases For High Quality, Low-Cost mRNA Manufacturing
Hear how engineered enzymes improve mRNA synthesis by reducing double-stranded RNA and lowering input costs. These advancements ensure high purity and integrity for complex, long-format therapeutic templates.
CONTACT INFORMATION
Primrose Bio
10790 Roselle St
San Diego, CA 92121
UNITED STATES
Phone: (858) 352-4400
FEATURED INSIGHTS
T7 Compatibility Is Not The Same As T7 Performance
T7-promoter workflows offer familiarity, but compatibility alone doesn't guarantee yield, purity, capping flexibility, or translatability as RNA programs advance into process development and scale-up.
-
![GettyImages-2287370476 RNA]( "Evaluating AG-Capped RNA Workflows For Yield, dsRNA And Translatability")
A strong capping result can hide deeper problems: elevated dsRNA, inconsistent yield across templates and UTRs, high cap analog needs, or poor translatability.
-
![GettyImages-2160715091 lab analysis]( "Usable RNA Output: A More Complete Way To Evaluate IVT Performance")
Total RNA yield alone doesn't tell the full story of IVT performance. Learn why usable target RNA output is the metric that matters most as programs advance toward manufacturing.
-
![GettyImages-2047658928 RNA Protein]( "Why RNA Diversity Is Raising The Bar For Platform-Aware IVT Design")
RNA therapeutics now span multiple construct types, each placing distinct demands on in vitro transcription design. Platform-aware IVT thinking is becoming essential as workflows grow more complex.
-
![GettyImages-2189138619 lab]( "5 IVT Design Considerations Before Scale-Up")
As RNA programs advance toward clinical manufacturing, five IVT design questions can help teams identify hidden process risks before scale-up exposes them.
-
![Primrose Bio - Hanmicap]( "A New Era Of mRNA Potency And Safety")
Selecting the right RNA polymerase and cap analog pairing significantly impacts mRNA yield, purity, and immunogenic safety, yet many production workflows still rely on a single industry-standard enzyme.
-
![Primrose - dsRNA 1]( "Lessons From Benchmarking Of dsRNA Across Polymerase Systems")
Not all low-dsRNA claims hold up under direct comparison. A 15-enzyme IVT study identifies the few systems that actually deliver across yield, integrity, and dsRNA simultaneously.
-
![Primrose Bio - Advancing RNA_Prima case study (002)]( "How Polymerase Selection Shapes IVT Outcomes: Insights From An Independent Evaluation")
dsRNA contamination starts with polymerase choice. See how engineered RNA polymerases cut dsRNA by more than 10x compared to wild-type T7 in independent IVT testing.
-
![Primrose Bio - Advancing RNA_PRIMA_Education+3rdPartyData_dsRNA-2026-03 (002)]( "dsRNA: Why Polymerase Choice Matters")
Polymerase selection during IVT shapes dsRNA levels, processing costs, and product quality. See how enzyme engineering reduces abortive transcripts and improves purity profiles for complex mRNA manufacturing applications.
-
![GettyImages-1409734937 RNA polymerase]( "RNA Polymerases For Efficient mRNA Manufacturing")
Precise enzyme selection in IVT reduces dsRNA byproducts and boosts capping efficiency. This ensures high-quality mRNA production while easing the burden of complex downstream purification processes.
-
![Advancing RNA_Primrose Scientific Poster]( "Advancing mRNA Therapeutics With High Performance RNA Polymerases")
Learn how optimized RNA polymerases enhance mRNA therapeutic quality and transcript integrity by increasing yield and capping efficiency while reducing double-stranded RNA impurities.
-
![Primrose Bio - Poster_Engineered Enzymes_Capping Analysis (002)]( "Engineered Enzymes Powering The Future Of mRNA Therapeutics")
Optimizing RNA polymerase selection significantly improves mRNA yield and purity while reducing dsRNA. Discover how advanced enzyme engineering enhances therapeutic manufacturing efficiency and safety.
SOLUTIONS
Match The Prima RNApols Enzyme To Your IVT Workflow
A comparison of purpose-built RNA polymerases engineered for IVT workflows, matched to template design and cap strategy to improve yield, capping efficiency, and byproduct reduction.
-
![Primrose Bio - Prima RNApols]( "Prima RNApols®: Enabling The Next Generation Of Bio-Therapeutics")
Engineered RNA polymerases deliver high-purity mRNA with greater yield, near-elimination of dsRNA byproducts, and superior capping efficiency, all while requiring fewer inputs than standard T7.
-
![Primrose Bio - primrose_bio___rna_logo]( "A Next-Gen Polymerase For Self-Amplifying mRNA")
Expanding on our innovative RNA polymerases, the Prima RNApols® ExTend Cap AU kit is designed to maximize yield and capping efficiency, and minimize dsRNA, during in vitro transcription (IVT) of saRNA.
-
![Primrose Bio - Advancing RNA_PRIMA_ProductLineUp-2026-03 (002)]( "Prima Product Line Up")
Discover how specialized RNA polymerase variants solve yield, purity, and capping challenges across different template lengths, with substantive improvements over standard T7 polymerase performance.
-
![Advancing RNA_Primrose Infographic]( "Enabling mRNA Manufacturing For RNA-Based Vaccines And Therapeutics")
Learn about next-generation RNA polymerases that support diverse cap analog chemistries and modified nucleotides, ensuring high capping efficiency and sequence integrity for complex therapeutics.
-
![Primrose Bio - Prima RNApols]( "ExTend Cap AU Kit: Next-Gen Polymerase For Self-Amplifying mRNA")
Achieve superior transcript purity and capping efficiency while reducing double-stranded RNA. This approach lowers manufacturing costs and simplifies purification for high-quality therapeutic production.
